CN102219860B - FGFR-Fc融合蛋白及其用途 - Google Patents

FGFR-Fc融合蛋白及其用途 Download PDF

Info

Publication number
CN102219860B
CN102219860B CN201110132218A CN201110132218A CN102219860B CN 102219860 B CN102219860 B CN 102219860B CN 201110132218 A CN201110132218 A CN 201110132218A CN 201110132218 A CN201110132218 A CN 201110132218A CN 102219860 B CN102219860 B CN 102219860B
Authority
CN
China
Prior art keywords
fusion protein
seq
fgfr
amino acid
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201110132218A
Other languages
English (en)
Chinese (zh)
Other versions
CN102219860A (zh
Inventor
房健民
李栋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rongchang bio Pharmaceutical (Yantai) Co., Ltd.
Original Assignee
RONGCHANG BIOLOGICAL ENGINEERING Co Ltd YANTAI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RONGCHANG BIOLOGICAL ENGINEERING Co Ltd YANTAI filed Critical RONGCHANG BIOLOGICAL ENGINEERING Co Ltd YANTAI
Priority to CN201110132218A priority Critical patent/CN102219860B/zh
Publication of CN102219860A publication Critical patent/CN102219860A/zh
Priority to DK16205128.8T priority patent/DK3173102T3/da
Priority to EP16205128.8A priority patent/EP3173102B1/en
Priority to BR112013022285-9A priority patent/BR112013022285B1/pt
Priority to KR1020137023245A priority patent/KR20130119978A/ko
Priority to EP12788998.8A priority patent/EP2711376B1/en
Priority to RU2013140184/10A priority patent/RU2560573C2/ru
Priority to CA2834584A priority patent/CA2834584C/en
Priority to JP2014505502A priority patent/JP2014513941A/ja
Priority to KR1020167001261A priority patent/KR101660336B1/ko
Priority to AU2012261412A priority patent/AU2012261412B2/en
Priority to PCT/CN2012/075706 priority patent/WO2012159550A1/zh
Application granted granted Critical
Publication of CN102219860B publication Critical patent/CN102219860B/zh
Priority to US13/842,345 priority patent/US9273137B2/en
Priority to US15/056,207 priority patent/US20160176945A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201110132218A 2011-05-20 2011-05-20 FGFR-Fc融合蛋白及其用途 Active CN102219860B (zh)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CN201110132218A CN102219860B (zh) 2011-05-20 2011-05-20 FGFR-Fc融合蛋白及其用途
JP2014505502A JP2014513941A (ja) 2011-05-20 2012-05-18 ＦＧＦＲ−Ｆｃ融合蛋白質およびその使用
AU2012261412A AU2012261412B2 (en) 2011-05-20 2012-05-18 FGFR-Fc fusion protein and use thereof
BR112013022285-9A BR112013022285B1 (pt) 2011-05-20 2012-05-18 Proteína de fusão de fgfr-fc e o seu uso
KR1020137023245A KR20130119978A (ko) 2011-05-20 2012-05-18 FGFR-Fc 융합단백질 및 용도
EP12788998.8A EP2711376B1 (en) 2011-05-20 2012-05-18 Fgfr-fc fusion protein and use thereof
RU2013140184/10A RU2560573C2 (ru) 2011-05-20 2012-05-18 FGF-R-Fc СЛИТЫЙ БЕЛОК И ЕГО ИСПОЛЬЗОВАНИЕ
CA2834584A CA2834584C (en) 2011-05-20 2012-05-18 Fgfr-fc fusion protein and use thereof
DK16205128.8T DK3173102T3 (da) 2011-05-20 2012-05-18 FGFR-FC-fusionsprotein og anvendelse deraf
KR1020167001261A KR101660336B1 (ko) 2011-05-20 2012-05-18 FGFR-Fc 융합단백질 및 용도
EP16205128.8A EP3173102B1 (en) 2011-05-20 2012-05-18 Fgfr-fc fusion protein and use thereof
PCT/CN2012/075706 WO2012159550A1 (zh) 2011-05-20 2012-05-18 FGFR-Fc融合蛋白及其用途
US13/842,345 US9273137B2 (en) 2011-05-20 2013-03-15 FGFR-Fc fusion proteins and the use thereof
US15/056,207 US20160176945A1 (en) 2011-05-20 2016-02-29 FGFR-FC Fusion Proteins and the Use Thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201110132218A CN102219860B (zh) 2011-05-20 2011-05-20 FGFR-Fc融合蛋白及其用途

Publications (2)

Publication Number Publication Date
CN102219860A CN102219860A (zh) 2011-10-19
CN102219860B true CN102219860B (zh) 2012-09-12

Family

ID=44776585

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201110132218A Active CN102219860B (zh) 2011-05-20 2011-05-20 FGFR-Fc融合蛋白及其用途

Country Status (11)

Country Link
US (2) US9273137B2 (https=)
EP (2) EP3173102B1 (https=)
JP (1) JP2014513941A (https=)
KR (2) KR20130119978A (https=)
CN (1) CN102219860B (https=)
AU (1) AU2012261412B2 (https=)
BR (1) BR112013022285B1 (https=)
CA (1) CA2834584C (https=)
DK (1) DK3173102T3 (https=)
RU (1) RU2560573C2 (https=)
WO (1) WO2012159550A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
WO2014018673A2 (en) * 2012-07-24 2014-01-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
SG10201703977UA (en) * 2013-05-23 2017-06-29 Five Prime Therapeutics Inc Methods of treating cancer
PT3102577T (pt) * 2014-02-07 2018-10-23 Principia Biopharma Inc Derivados de quinolona como inibidores do recetor do fator de crescimento de fibroblastos
CN105983093A (zh) * 2015-02-11 2016-10-05 烟台荣昌生物工程有限公司 血管新生因子融合蛋白在制备用于治疗与血管新生相关的眼部疾病药物中的应用
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
JP7247097B2 (ja) * 2017-03-17 2023-03-28 バクシム アクチェンゲゼルシャフト がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン
AU2019394227B2 (en) 2018-12-07 2023-04-06 Remegen Co., Ltd. Bifunctional angiogenesis inhibitor and use thereof
CN116143941B (zh) * 2022-09-08 2024-06-04 浙江省血液中心 一种KIR3DL1-IgG-Fc融合重组蛋白、应用及试剂盒
CN116199744B (zh) * 2023-03-23 2024-06-25 湖南中晟全肽生物科技股份有限公司 一种结合fgfr2受体的多肽及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656728B1 (en) * 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
CN101589145A (zh) * 2006-11-28 2009-11-25 申特莱恩公司 经修饰的具有改良生物活性的可溶性FGF受体Fc融合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
DE102005007665A1 (de) * 2005-02-19 2006-08-31 Degussa Ag Folie auf Basis eines Polyamidblends
EP2083081A1 (en) * 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
JP2009539412A (ja) * 2006-06-12 2009-11-19 レセプター バイオロジックス， インコーポレイテッド 汎細胞表面レセプター特異的な治療薬
RU2341198C2 (ru) * 2006-11-27 2008-12-20 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ оценки ангиогенных факторов при химиотерапии рака молочной железы
AR063975A1 (es) * 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
EP2318529B1 (en) * 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
LT2498799T (lt) * 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
CN102219859B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656728B1 (en) * 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
CN101589145A (zh) * 2006-11-28 2009-11-25 申特莱恩公司 经修饰的具有改良生物活性的可溶性FGF受体Fc融合物

Also Published As

Publication number Publication date
BR112013022285A2 (pt) 2016-12-06
CN102219860A (zh) 2011-10-19
US20160176945A1 (en) 2016-06-23
US20130195864A1 (en) 2013-08-01
WO2012159550A1 (zh) 2012-11-29
KR20160011241A (ko) 2016-01-29
EP2711376A1 (en) 2014-03-26
BR112013022285B1 (pt) 2020-05-12
EP3173102A1 (en) 2017-05-31
CA2834584A1 (en) 2012-11-29
US9273137B2 (en) 2016-03-01
EP2711376A4 (en) 2015-06-03
EP2711376B1 (en) 2018-07-25
JP2014513941A (ja) 2014-06-19
KR20130119978A (ko) 2013-11-01
RU2013140184A (ru) 2015-07-10
EP3173102B1 (en) 2019-11-20
AU2012261412A1 (en) 2013-08-29
CA2834584C (en) 2019-05-14
AU2012261412B2 (en) 2016-02-25
KR101660336B1 (ko) 2016-09-27
DK3173102T3 (da) 2020-02-24
RU2560573C2 (ru) 2015-08-20

Similar Documents

Publication Publication Date Title
CN102219860B (zh) FGFR-Fc融合蛋白及其用途
US9522949B2 (en) Fusion protein for antagonizing angiogenesis inducible factors and uses thereof
CN106459218B (zh) 新的重组双功能融合蛋白、其制剂和用途
KR101658247B1 (ko) 모듈 인식 도메인을 통한 항체 표적화
JP6519090B2 (ja) 血管内皮成長因子融合タンパク質
US9957313B2 (en) FGFR-FC fusion proteins and the use thereof
JP6138304B2 (ja) ＦＧＦＲ−Ｆｃ融合蛋白質およびその使用
WO2016191765A1 (en) Fgfr-fc fusion proteins and the use thereof
HK1195778A (en) Fgfr-fc fusion protein and use thereof
HK1195778B (en) Fgfr-fc fusion protein and use thereof
HK1195779A (en) Fusion protein for antagonizing angiogenesis inducible factors and uses thereof
HK1195779B (en) Fusion protein for antagonizing angiogenesis inducible factors and uses thereof
EP3486254A1 (en) Cancer treatment composition for inhibiting tumor angiogenesis, containing vegf deep blocker, and preparation method therefor
Ferrara 2 Vascular Endothelial Growth Factor: Basic Biology and Clinical Applications

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20111019

Assignee: Yantai Rongchang Pharmacy Co., Ltd.

Assignor: Rongchang Biological Engineering Co., Ltd., Yantai

Contract record no.: 2012370000208

Denomination of invention: FGFR-Fc fusion protein and applications thereof

License type: Exclusive License

Record date: 20120831

C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: 264006 Yantai economic and Technological Development Zone, Beijing, No. 58 Middle Road, Shandong

Patentee after: Rongchang Biological Engineering Co., Ltd., Yantai

Address before: 264006 Yantai economic and Technological Development Zone, Shandong, No. 1 Rongchang Road

Patentee before: Rongchang Biological Engineering Co., Ltd., Yantai

C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: 264006 Yantai economic and Technological Development Zone, Beijing, No. 58 Middle Road, Shandong

Patentee after: Rongchang bio Pharmaceutical (Yantai) Co., Ltd.

Address before: 264006 Yantai economic and Technological Development Zone, Beijing, No. 58 Middle Road, Shandong

Patentee before: Rongchang Biological Engineering Co., Ltd., Yantai

TR01 Transfer of patent right

Effective date of registration: 20170515

Address after: 264006 Yantai economic and Technological Development Zone, Beijing, No. 58 Middle Road, Shandong

Patentee after: Yantai Rongchang Pharmacy Co., Ltd.

Address before: 264006 Yantai economic and Technological Development Zone, Beijing, No. 58 Middle Road, Shandong

Patentee before: Rongchang bio Pharmaceutical (Yantai) Co., Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20190729

Address after: 264006 Yantai economic and Technological Development Zone, Beijing, No. 58 Middle Road, Shandong

Patentee after: Rongchang bio Pharmaceutical (Yantai) Co., Ltd.

Address before: 264006 Yantai economic and Technological Development Zone, Beijing, No. 58 Middle Road, Shandong

Patentee before: Yantai Rongchang Pharmacy Co., Ltd.

TR01 Transfer of patent right
EC01 Cancellation of recordation of patent licensing contract

Assignee: Yantai Rongchang Pharmacy Co., Ltd.

Assignor: Rongchang Biopharmaceutical (Yantai) Co., Ltd.

Contract record no.: 2012370000208

Date of cancellation: 20191104

EC01 Cancellation of recordation of patent licensing contract
EM01 Change of recordation of patent licensing contract

Change date: 20191104

Contract record no.: 2012370000208

Assignor after: Rongchang Biopharmaceutical (Yantai) Co., Ltd.

Assignor before: Rongchang Biological Engineering Co., Ltd., Yantai

EM01 Change of recordation of patent licensing contract